Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTMVEW)

Drug Name

JCAR014 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-hodgkin lymphoma	2B33.5	Phase 1/2	[1]
B-cell lymphoma	2A86	Phase 1	[2]
B-cell non-hodgkin lymphoma	2B33.5	Phase 1	[3]
Diffuse large B-cell lymphoma	2A81	Phase 1	[2]
Mediastinal large B-cell lymphoma	2A60.32	Phase 1	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[5]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[6]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[7]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[8]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[9]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[10]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[11]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[12]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041075)
2	ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
5	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
10	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
11	Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
12	A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
13	ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL